Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0146

Advisory board · Dr. Gabriel Rossi

08 May 2026 · In person · Dr. Gabriel Rossi, Guy's and St Thomas' · MSL Dr. Anna Becker · Nephrada

ReviewedVeeva CRMENG-0146—

Capture insight from this engagement

Location: Guy's and St Thomas'
Therapeutic area: Nephrology
Country: United Kingdom
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: ABDr. Anna BeckerMSL, Nephrology (DACH)
Product: Nephrada (nephradin)

Topics discussed

Treatment burden and fatigue
Steroid-sparing strategies

Scientific content used

NPH mechanism-of-action deck

Questions raised

No questions recorded.

Notes

Advisory board with renal pathologist at Guy's and St Thomas'. Discussed treatment burden and fatigue, steroid-sparing strategies.

Insights captured (1)

Capture insight

INS-0059Low
Treatment burden and fatigue
Treatment burden and fatigue: recurring question reported by renal pathologist (GB).
Closed

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 3
Depth of exchange: 1
Actionability: 1

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0146

Audit history (0)

All create, update and approval events for this record

No audit events in sample data